Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
Nightstar acquisition further bolsters Biogen’s pipeline with the addition of two mid- to late-stage clinical assets as well as preclinical programs
CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. The total transaction value was approximately $800 million, after taking into account expected transaction expenses and cash at closing. NST’s common stock will no longer be listed for trading on the Nasdaq Global Select Market.
NST’s lead asset is NSR-REP1 for the treatment of choroideremia (CHM), a rare, degenerative, X-linked inherited retinal disorder, which leads to blindness and has no approved treatments. CHM primarily affects males and is caused by loss of function in the CHM gene which encodes the Rab escort protein-1 (REP-1). Initially, patients with CHM experience poor night vision, and over time progressive visual loss ultimately leads to complete blindness.
NSR-RPGR is NST’s second clinical program for the treatment of X-linked retinitis pigmentosa (XLRP), which is also a rare inherited retinal disease primarily affecting males with no approved treatments. XLRP is characterized by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene leading to a lack of active protein transport in photoreceptors. This abnormality leads to loss of photoreceptor cells, resulting in retinal dysfunction by adolescence and early adulthood, progressing to legal blindness when patients reach their 40s.
“Today marks a significant achievement for Biogen,” said Michel Vounatsos, Biogen’s Chief Executive Officer. “The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities. We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”
Goldman, Sachs & Co. acted as financial advisor to Biogen, and Ropes & Gray LLP acted as legal counsel.
Centerview Partners acted as financial advisor to NST, and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal counsel.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com . To learn more, please visit www.biogen.com and follow us on social media – Twitter , LinkedIn , Facebook , YouTube .
Biogen Safe Harbor
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to the potential benefits and results that may be achieved through the acquisition; risks and uncertainties associated with drug development and commercialization; the potential benefits, safety and efficacy of investigational therapies, including NSR-REP1 and NSR-RPGR; our strategy and plans; the potential of our commercial business and pipeline programs, including NSR-REP1 and NSR-RPGR; and our capital allocation and investment strategy. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: uncertainty as to whether the anticipated benefits of the acquisition can be achieved; our ability to successfully integrate NST’s operations and employees; risks of unexpected costs or delays; uncertainty of success in the development and potential commercialization of NSR-REP1 and NSR-RPGR, which may be impacted by, among other things, the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of NSR-REP1 and NSR-RPGR; we may encounter other unexpected hurdles, which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions or failure to protect intellectual property and other proprietary rights; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; and product liability claims. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risks factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission.
These statements are based on our current beliefs and expectations and speak only as of the date of this news release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
+ 1 617 679 4945
+1 781 464 2442
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Cineworld Group and Cinionic Strike 1,000+ Unit Deal to Roll Out Acclaimed Barco Laser Projectors to Theaters Worldwide17.6.2019 18:05:00 CEST | Pressemelding
Cineworld embarks on global renewal with Cinionic, powered by award-winning projection portfolio and enhanced services KORTRIJK, Belgium, June 17, 2019 (GLOBE NEWSWIRE) -- Cinionic, the Barco, CGS, and ALPD cinema joint venture providing a new visual standard with enhanced services and technology solutions, announces a significant expansion in its relationship with one of the world’s largest theater chains, Cineworld Group plc (LON:CINE), to continue delivering an elevated movie-going experience for audiences worldwide. Cinionic will illuminate Cineworld Group operated theaters in the U.S., EU and UK with enhanced services and award-winning portfolio of Barco laser projectors, including the newly launched Barco Series 4. Over the next 18 months, Cineworld will upgrade and deploy over 1,000 projectors worldwide with Barco Laser solutions to deliver a new visual standard in cinema, supported by Barco Alchemy media servers and maintained for the next decade through Cinionic’s enhanced ser
Rock Tech Engages KBM Resources Group for LiDAR Survey at Georgia Lake17.6.2019 14:15:00 CEST | Pressemelding
VANCOUVER, British Columbia, June 17, 2019 (GLOBE NEWSWIRE) -- Rock Tech Lithium Inc. (the "Company" or “Rock Tech”) (TSX-V: RCK; Frankfurt: RJIB) is pleased to announce that it has engaged KBM Resources Group (“KBM”) to complete a LiDAR and high-resolution imagery survey at its 100%-owned Georgia Lake lithium project in Ontario, Canada. The aerial acquisition of LiDAR and digital photography will cover the Nama Creek main zone and adjacent areas of the Georgia Lake lithium project. The LiDAR survey, with a relatively high resolution of 10 laser points per square metre and an absolute accuracy of 10 cm vertical and 20 cm horizontal, will produce LAS files with classified ground points including a bare earth model and georeferenced orthoimagery. “The ideal time to fly this survey is after the snow melt and before leaf-out,” commented Martin Stephan, Rock Tech’s Chief Executive Officer. “These conditions, combined with a favourable regional weather forecast, shall make for a successful L
Major HAProxy Releases Increase Support for Cloud-Native and Containerized Application Architectures17.6.2019 14:00:00 CEST | Pressemelding
Key Community Releases Include HAProxy 2.0, HAProxy Data Plane API and HAProxy Kubernetes Ingress Controller WALTHAM, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- HAProxy Technologies, provider of the world’s fastest and most widely-used software load balancer, today announced that the HAProxy community has released HAProxy 2.0 and several other key products that make it easier to extend, configure and manage HAProxy in cloud-native and containerized environments. The company also announced its inaugural community user conference, HAProxyConf 2019, which will take place in Amsterdam, Netherlands on November 12th and 13th, 2019. “The release of HAProxy 2.0 along with the new HAProxy Data Plane API and HAProxy Kubernetes Ingress Controller mark the culmination of a significant re-architecture of HAProxy to add the flexibility and features needed to optimize support for modern application architectures,” said Willy Tarreau, HAProxy community lead and HAProxy Technologies CTO. “I am extremely
Carpenter Technology and Israel Aerospace Industries Announce Collaboration to Produce Commercial Aircraft Additive Parts17.6.2019 14:00:00 CEST | Pressemelding
Le Bourget, FRANCE, June 17, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) and Israel Aerospace Industries (IAI) today announced their collaboration to produce additively manufactured components for a serial production commercial aircraft. This collaboration will result in IAI’s first metallic additively-produced parts, which are expected to provide significant manufacturing benefits and lay the groundwork for future design improvements and enhancements. IAI is working closely with Israel’s Civil Aviation Authority for approval of the parts, which when accomplished will represent the first time this technology has been approved for commercial use in Israel. Carpenter Technology, through its Carpenter Additive business unit, is producing the parts and providing supporting information to assist with their approval. “Together, Carpenter Additive and IAI are pioneering the use of this technology for new platforms and applications,” said Marshall Akins, Carpenter Tec
Brookfield Asset Management Announces Results of Annual and Special Meeting of Shareholders17.6.2019 12:55:00 CEST | Pressemelding
BROOKFIELD, NEWS, June 17, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX: BAM.A, NYSE: BAM, Euronext: BAMA) today announced that at the company’s annual and special meeting of shareholders held on June 14, 2019 in Toronto, over 85% of Class A Limited Voting Shares (“Class A Shares”) voted in favour of a new management share option plan. In addition, at the meeting all eight nominees proposed for election to the board of directors by holders of Class A Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares (“Class B Shares”) were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 731,503,129 99.60 2,926,448 0.40 Angela F. Braly 730,750,957 99.50 3,67
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®17.6.2019 12:00:00 CEST | Pressemelding
Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 years Seroprotection rates four weeks post-3rd vaccination of Sci-B-Vac® vs. Engerix-B® were statistically significantly higher in key subgroup analyses of adults age ≥ 18 years No safety signals observed – safety and tolerability consistent with known profile of the vaccine With positive PROTECT data, pending successful completion of CONSTANT study, submissions of BLA/MAA for approval in U.S., Europe, and Canada expected to begin mid-year 2020 VBI to host conference call and webcast today, Monday, June 17, 2019 at 8:00 AM ET CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive top-line results from the randomized, double-blind, pivotal Phase 3 study, PROTECT, designed to